¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¼¼°è ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀåÀº 2023³â ¾à 1,947¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 13.15% ÀÌ»óÀÇ °ßÁ¶ÇÑ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
³ª³ë±â¼úÀº 100 ³ª³ë¹ÌÅͺ¸´Ù ÀÛÀº ³ª³ë ÀÔÀÚ¸¦ »ç¿ëÇÏ´Â ¼Ò¸³ÀÚ ¶Ç´Â ºÐÀÚ ¼öÁØÀÇ Àç·á °úÇÐÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ³ª³ë ÀÔÀÚ´Â À̹Ì¡ ¹æ¹ýÀÇ À̹Ì¡ Á¦Á¦, »õ·Î¿î Áø´Ü µµ±¸, ¹ÙÀÌ¿À ÀÓÇöõÆ®, Á¶Á÷ °øÇÐ, ÀǾàǰ, Ç¥Àû ¾à¹° Àü´Þ µî ÇコÄÉ¾î ºÐ¾ß¿¡¼ Å« ÀáÀçÀû ÀÀ¿ë °¡´É¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ª³ëÀÔÀڴ ǥ¸é ´ë ºÎÇǺñ°¡ Å©±â ¶§¹®¿¡ ¸ÅÅ©·Î ¹× ¸¶ÀÌÅ©·Î Å©±âÀÇ ÀÔÀÚ¿¡ ºñÇØ ´õ ³ôÀº ¾à¹° ºÎÇϰ¡ °¡´ÉÇϱ⠶§¹®¿¡ Ç¥Àû ¾à¹° Àü´Þ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ³ª³ë±â¼úÀÇ ¹ßÀüÀº Á¶±â Áø´Ü, Áúº´ °ËÁø, È¿°úÀûÀÎ ¾à¹° Àü´Þ ¸ÞÄ¿´ÏÁò, °Ç° ¸ð´ÏÅ͸µÀ» ÅëÇØ »ç¶÷µéÀÇ °Ç° ÁõÁø¿¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ³ª³ë±â¼úÀÌ ÁÖµµÇÏ´Â ÇコÄÉ¾î ¼ºñ½º´Â ¿¹¹æÀû °Ç°°ü¸®¸¦ Áß½ÃÇϸç, ±âÁ¸ÀÇ ¹æ¹ýÀ̳ª °Ë»ç°¡ °¡´ÉÇϱâ ÈξÀ Àü¿¡ ½ÅüÀû À§Çè°ú º´¿ø±ÕÀ» °¨ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀåÀº ½ÉÇ÷°ü Áúȯ, Á¤Çü¿Ü°ú Áúȯ, ºñ¸¸, ¾Ï, ½ÅÀå Áúȯ, ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯ Áõ°¡·Î ÀÎÇØ °·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ³ë·É Àα¸ Áõ°¡¿Í ´Ù¾çÇÑ Áúº´À» Ä¡·áÇϱâ À§ÇÑ ³ª³ëÀÇÇÐ ÀÀ¿ë¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä Áõ°¡¿Í ÀÇ·á¿ë ³ª³ë±â¼ú¿¡ ´ëÇÑ ¿¬±¸ ÀÚ±Ý Áõ°¡´Â ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¾ö°ÝÇÑ ±ÔÁ¦, ±ä ½ÂÀÎ ±â°£, ³ª³ë±â¼ú ±â¹Ý ÀÇ·á±â±â¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë µîÀÌ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î ³ª³ë ÀǾàǰÀÇ °³¹ß¿¡´Â »ó´çÇÑ ½Ã°£ÀÌ ¼Ò¿äµÇ±â ¶§¹®¿¡ ½ÃÀå È®´ë¿¡ ÇѰ谡 ÀÖ½À´Ï´Ù.
¼¼°è ÇコÄÉ¾î ³ª³ë±â¼ú ½ÃÀå Á¶»ç¿¡¼ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀ¸·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áö¿ªÀÌ ÀÖÀ¸¸ç, ºÏ¹Ì´Â ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, dzºÎÇÑ ¿¬±¸ ÀÚ±Ý ¹× ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç·Î ÀÎÇØ 2023³â ÇコÄÉ¾î ³ª³ë±â¼ú ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ÅõÀÚ Áõ°¡, ÀÎÁöµµ Çâ»ó, ȯÀÚ Àα¸ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå : ÁÖ¿ä ¿ä¾à
- ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022³â-2032³â)
- Áö¿ªº° °³¿ä
- ºÎ¹®º° °³¿ä
- ¸ð´Þ¸®Æ¼º°
- ÀûÀÀÁõº°
- ¿ëµµº°
- ÁÖ¿ä µ¿Çâ
- °æ±âÈÄÅðÀÇ ¿µÇâ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦2Àå ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå Á¤ÀÇ¿Í Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Á¶»ç ¸ñÀû
- ½ÃÀåÀÇ Á¤ÀÇ
- Á¶»çÀÇ ÀüÁ¦Á¶°Ç
- Æ÷ÇÔ°ú Á¦¿Ü
- Á¦ÇÑ »çÇ×
- °ø±ÞÃø ºÐ¼®
- °¡¿ë¼º
- ÀÎÇÁ¶ó
- ±ÔÁ¦ ȯ°æ
- ½ÃÀå °æÀï
- °æÁ¦¼º(¼ÒºñÀÚ ½ÃÁ¡)
- ¼ö¿äÃø ºÐ¼®
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ±â¼ú Áøº¸
- ģȯ°æ
- ¼ÒºñÀÚ Àǽİú ¼ö¿ë
- Á¶»ç ¹æ¹ý
- Á¶»ç ´ë»ó³âµµ
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå : »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ¹ÙÀ̾îÀÇ ±³¼··Â
- ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷°£ °æÀï °ü°è
- Porter's Five Forces ¸ðµ¨¿¡ ´ëÇÑ ¹Ì·¡Àû Á¢±Ù
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PESTEL ºÐ¼®
- Á¤Ä¡
- °æÁ¦
- »çȸ
- 񃬣
- ȯ°æ
- ¹ý·ü
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- ÆÄ±«Àû µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °ßÇØ
- ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð ¹× Á¦¾È
Á¦5Àå ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¸ð´Þ¸®Æ¼º°, 2022-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå : ¸ð´Þ¸®Æ¼º° ¸ÅÃâ µ¿Ç⠺м®, 2022³â/2032³â
Á¦6Àå ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÀûÀÀÁõº°, 2022-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå : ÀûÀÀÁõº° ¸ÅÃâ µ¿Ç⠺м®, 2022³â/2032³â
- ÀÓ»ó Á¾¾ç
- °¨¿°Áõ
- ÀÓ»ó ½ÉÀ庴
- Á¤Çü¿Ü°ú
- ½Å°æ
- ºñ´¢±â
- ¾È°ú
- ¸é¿ª
- ±âŸ
Á¦7Àå ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°, 2022-2032³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå : ¿ëµµº° ¸ÅÃâ µ¿Ç⠺м®, 2022³â/2032³â
- ¾à¹°Àü´Þ
- Àç»ýÀÇ·á
- ÀÓÇöõÆ®
- Áø´Ü
- ¿µ»ó
- ¹é½Å
- ±âŸ
Á¦8Àå ¼¼°èÀÇ ÇコÄÉ¾î ³ª³ëÅ×Å©³î·¯Áö ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°, 2022-2032³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- Pfizer Inc.
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì)
- Á¦Ç° °³¿ä
- ½ÃÀå Àü·«
- Celgene Corporation
- Abbott Laboratories
- Taiwan Liposome Company Ltd.
- GE Healthcare
- Johnson & Johnson
- Leadiant Biosciences Inc.
- Sanofi SA
- Merck & Company Inc.
- Luminex Corporation
Á¦10Àå Á¶»ç °úÁ¤
LSH 24.09.04
Global Healthcare Nanotechnology Market is valued approximately at USD 194.73 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 13.15% over the forecast period 2024-2032. Nanotechnology is the science of materials at the subatomic or molecular level, which involves the use of nanoparticles particles smaller than 100 nanometers. These nanoparticles have substantial potential applications in the healthcare sector, such as imaging agents in imaging methods, new diagnostic tools, bio-implants, tissue engineering, pharmaceuticals, and targeted drug delivery. These nanoparticles are widely used for targeted drug delivery treatments due to their larger surface-to-volume ratio, which allows for higher drug loading compared to macro- and micro-size particles. The advancements in nanotechnology can help improve population health through early diagnosis and disease screening, effective drug delivery mechanisms, and health monitoring. Nanotechnology-driven healthcare services emphasize preventative healthcare management, detecting physical risks and pathogens long before traditional methods and examinations can.
The Global Healthcare Nanotechnology Market is experiencing robust growth driven by rising incidences of cardiovascular, orthopedic, and chronic diseases such as obesity, cancer, kidney disorders, and diabetes. The growing geriatric population and increasing awareness of nanomedicine applications for treating various diseases further propel market growth. Additionally, higher unmet medical needs and increased research funding for nanotechnology in healthcare significantly contribute to market expansion. However, stringent regulations, time-consuming approvals, and high costs associated with nanotechnology-based medical devices hinder market growth. Moreover, the development of newer nanomedicines requires considerable time, which limits market expansion.
The key regions considered for the Global Healthcare Nanotechnology Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America is expected to dominate the healthcare nanotechnology market due to its advanced healthcare infrastructure, substantial research funding, and presence of key market players. The Asia-Pacific region is projected to experience the highest growth rate during the forecast period, driven by increasing healthcare investments, rising awareness, and a growing patient population.
Major market players included in this report are:
- Pfizer Inc.
- Celgene Corporation
- Abbott Laboratories
- Taiwan Liposome Company Ltd.
- GE Healthcare
- Johnson & Johnson
- Leadiant Biosciences Inc.
- Sanofi SA
- Merck & Company Inc.
- Luminex Corporation
The detailed segments and sub-segment of the market are explained below:
By Modality
By Indication
- Clinical oncology
- Infectious diseases
- Clinical cardiology
- Orthopedics
- Neurology
- Urology
- Ophthalmology
- Immunology
- Others
By Application
- Drug delivery
- Regenerative medicine
- Implants
- Diagnostic
- Imaging
- Vaccines
- Others
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLA
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market
Table of Contents
Chapter 1. Global Healthcare Nanotechnology Market Executive Summary
- 1.1. Global Healthcare Nanotechnology Market Size & Forecast (2022- 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Modality
- 1.3.2. By Indication
- 1.3.3. By Application
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Healthcare Nanotechnology Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Healthcare Nanotechnology Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Increasing incidences of chronic diseases
- 3.1.2. Growth in geriatric population
- 3.1.3. Rise in research funding
- 3.2. Market Challenges
- 3.2.1. Stringent regulations and time-consuming approvals
- 3.2.2. High costs associated with nanotechnology-based medical devices
- 3.3. Market Opportunities
- 3.3.1. Advancements in nanotechnology
- 3.3.2. Growing awareness of nanomedicine
Chapter 4. Global Healthcare Nanotechnology Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top investment opportunity
- 4.4. Top winning strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Healthcare Nanotechnology Market Size & Forecasts by Modality 2022-2032
- 5.1. Segment Dashboard
- 5.2. Global Healthcare Nanotechnology Market: Modality Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Treatment
- 5.2.2. Diagnostics
Chapter 6. Global Healthcare Nanotechnology Market Size & Forecasts by Indication 2022-2032
- 6.1. Segment Dashboard
- 6.2. Global Healthcare Nanotechnology Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Clinical oncology
- 6.2.2. Infectious diseases
- 6.2.3. Clinical cardiology
- 6.2.4. Orthopedics
- 6.2.5. Neurology
- 6.2.6. Urology
- 6.2.7. Ophthalmology
- 6.2.8. Immunology
- 6.2.9. Others
Chapter 7. Global Healthcare Nanotechnology Market Size & Forecasts by Application 2022-2032
- 7.1. Segment Dashboard
- 7.2. Global Healthcare Nanotechnology Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Drug delivery
- 7.2.2. Regenerative medicine
- 7.2.3. Implants
- 7.2.4. Diagnostic
- 7.2.5. Imaging
- 7.2.6. Vaccines
- 7.2.7. Others
Chapter 8. Global Healthcare Nanotechnology Market Size & Forecasts by Region 2022-2032
- 8.1. North America Healthcare Nanotechnology Market
- 8.1.1. U.S. Healthcare Nanotechnology Market
- 8.1.1.1. Modality breakdown size & forecasts, 2022-2032
- 8.1.1.2. Indication breakdown size & forecasts, 2022-2032
- 8.1.1.3. Application breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Healthcare Nanotechnology Market
- 8.2. Europe Healthcare Nanotechnology Market
- 8.2.1. U.K. Healthcare Nanotechnology Market
- 8.2.2. Germany Healthcare Nanotechnology Market
- 8.2.3. France Healthcare Nanotechnology Market
- 8.2.4. Spain Healthcare Nanotechnology Market
- 8.2.5. Italy Healthcare Nanotechnology Market
- 8.2.6. Rest of Europe Healthcare Nanotechnology Market
- 8.3. Asia-Pacific Healthcare Nanotechnology Market
- 8.3.1. China Healthcare Nanotechnology Market
- 8.3.2. India Healthcare Nanotechnology Market
- 8.3.3. Japan Healthcare Nanotechnology Market
- 8.3.4. Australia Healthcare Nanotechnology Market
- 8.3.5. South Korea Healthcare Nanotechnology Market
- 8.3.6. Rest of Asia Pacific Healthcare Nanotechnology Market
- 8.4. Latin America Healthcare Nanotechnology Market
- 8.4.1. Brazil Healthcare Nanotechnology Market
- 8.4.2. Mexico Healthcare Nanotechnology Market
- 8.4.3. Rest of Latin America Healthcare Nanotechnology Market
- 8.5. Middle East & Africa Healthcare Nanotechnology Market
- 8.5.1. Saudi Arabia Healthcare Nanotechnology Market
- 8.5.2. South Africa Healthcare Nanotechnology Market
- 8.5.3. Rest of Middle East & Africa Healthcare Nanotechnology Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Pfizer Inc.
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Market Strategies
- 9.3.2. Celgene Corporation
- 9.3.3. Abbott Laboratories
- 9.3.4. Taiwan Liposome Company Ltd.
- 9.3.5. GE Healthcare
- 9.3.6. Johnson & Johnson
- 9.3.7. Leadiant Biosciences Inc.
- 9.3.8. Sanofi SA
- 9.3.9. Merck & Company Inc.
- 9.3.10. Luminex Corporation
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes